Press Release

<p><strong>Contest Winner Announced at ASRM</strong> </p> <table> <tr> <td valign="top"><p><b>Contact:</b></p></td> <td width="20" valign="top"></td> <td><p>Kelly Laban<br> Kovak-Likly Communications<br> (203)762-8833 or</p></td> </tr> </table> <p>PHILADELPHIA - October 18, 2004 - Ferring Pharmaceuticals, manufacturer of a family of fertility treatments, today announced that Jennifer and Stephen Lyon, of Overland Park, Kansas, are the grand prize winners of its <i>My Little Miracle</i> Essay Contest. Wayne Anderson, president of Ferring, presented the Lyons with a $10,000 check to be deposited in an education fund for their one-year-old daughters, Ella and Catherine, born with the help of Ferring&#8217;s Repronex&trade; (menotropins for injection, USP). The presentation was made on October 17 at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia. </p> <p>&#8220;Although it was a different kind of surprise, I think I was almost as shocked to hear that we won this contest as I was to hear we were expecting twins,&#8221; said Jennifer Lyon. &#8220;And here I was thinking that as a mother of three infants, being shocked was a thing of the past. The education fund is another wonderful gift from the company that has already made a priceless contribution to our miracle family.&#8221; </p> <p>&#8220;We are delighted to offer this program to help fertility patients contribute to their children&#8217;s future,&#8221; said Wayne Anderson, president, Ferring Pharmaceuticals. &#8220;Ferring is committed to providing patients with safe, effective and affordable fertility treatments. This program is an extension of Ferring&#8217;s support of its patients.&#8221; </p> <p>The <i>My Little Miracle</i> essay contest celebrated the births of children made possible through Ferring&#8217;s fertility treatments, Bravelle&trade; (urofollitropin for injection, purified) and Repronex&trade; (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country. </p> <p><strong>The Contest Winners</strong><br/> The Lyons had tried to conceive unsuccessfully for almost three years when they turned to adoption to start a family. At the same time, Doctors Daniel L. Stewart and Dan L. Gehlbach at Reproductive Medicine &amp; Infertility at Shawnee Mission Medical Center urged them to consider one more option&ndash;an intrauterine insemination (IUI) treatment cycle with Repronex&trade;. They agreed and began treatment, but continued to pursue adoption. Six weeks after completing the required papers for adoption, the Lyons were notified that they had been chosen to be the parents of a young boy. Their joy was then doubled when they learned that Jennifer was pregnant&ndash;with twins. In her essay, Jennifer speaks of her experience: </p> <p><i>&#8220;It&#8217;s a typical afternoon. Laundry piles everywhere. &#8216;Teddy Bear Picnic&#8217; is on its fourteenth playing, as someone has hidden the stereo remote. Our twenty-month old, Jackson, donning one high-heeled shoe, is trying to perfect his summersault in the laundry. Fifteen month-old Ella, diaper self-removed, is on a naked mission to &#8216;love&#8217; (a.k.a. torture) the cat, while her twin Catherine is on tiptoes pounding out a baby sonata on the piano. I can&#8217;t remember a time when this house was quiet or clean, and I don&#8217;t really care. &hellip; They climb everything in sight, know how to really shake it when provided with the right tunes, and give the best hugs know, to man and most furry creatures. They don&#8217;t realize they&#8217;re our miracles&hellip;but we do.&#8221;</i> </p> <p>John and Fiona Doskocz, of Northville, Michigan, are the runner-up winners and will receive a $5,000 education fund for their nine-month-old sons, Evan and Tyler. Ten honorable mention winners will each receive a $1,000 education fund for their children born with the help of Ferring&#8217;s fertility treatments. </p> <p><strong>About Bravelle&trade; and Repronex&trade;</strong> </p> <p>Bravelle&trade;, a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle&trade;, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle&trade;, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression. </p> <p>Repronex&trade; is the only human menopausal gonadotropin (hMG) on the market and is approved for both subcutaneous and intramuscular administration. </p> <p>Bravelle&trade; and Repronex&trade;, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. </p> <p>Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex&trade; and/ or Bravelle&trade; may result in multiple gestations. </p> <p><strong>About Ferring Pharmaceuticals</strong><br/> Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle&trade;, Repronex&trade; and Novarel&trade; in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit <a href="" target="_blank"></a> or <a href="" target="_blank"></a>. </p>